This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.
1. CJ Murray , AD Lopez . Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet. 1997; 349: 1498–1504.
2. C Murray , AD Lopez . Evidence-based health policy—lessons from the Global Burden of Disease Study. Science. 1996; 274(5288): 740–743.
3. PE Greenberg , RC Kessler , HG Birnbaum , etal. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry. 2003; 64: 1465–1475.
5. AJ Rush , ME Thase , S Dubé . Research issues in the study of difficult-to-treat depression. Biol Psychiatry. 2003; 53: 743–753.
7. M Fava , AJ Rush , M Trivedi , etal. Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatr Clin North Am. 2003; 26: 457–494.
8. AJ Rush , M Fava , SR Wisniewski , etal. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials. 2004; 25: 119–142.
9. MH Trivedi , AJ Rush , SR Wisniewski , etal. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D implications for clinical practice. Am J Psychiatry. 2006; 163: 28–40.
10. AJ Rush , MH Trivedi , SR Wisniewski , etal. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med. 2006; 354: 1231–1242.
11. M Fava , AJ Rush , SR Wisniewski , etal. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: A STAR*D report. Am J Psychiatry. 2006; 163: 1161–1172.
12. PJ McGrath , JW Stewart , M Fava , etal. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry. 2006; 163: 1531–1541.
13. AA Nierenberg , M Fava , MH Trivedi , etal. A comparison of lithium and T3 augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry. 2006; 163: 1519–1530.
14. AJ Rush , MH Trivedi , SR Wisniewski , etal. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006; 163: 1905–1917.
15. P Janicak , JP O'Reardon , SM Sampson , etal. Transcranial magnetic stimulation in the treatment of major depressive disorder: a comprehensive summary of safety experience from acute exposure, extended exposure, and during reintroduction treatment. J Clin Psychiatry. 2008; 69: 222–232.
16. PG Janicak , Z Nahas , SH Lisanby , etal. Durability of clinical benefit with transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant major depression: assessment of relapse during a 6-month, multisite, open-label study. Brain Stimul. 2010; 3: 187–199.
17. MS George , SH Lisanby , D Avery , etal. Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. Arch Gen Psychiatry. 2010; 67: 507–516.
18. DH Avery , KE Isenberg , SM Sampson , etal. Transcranial magnetic stimulation in the acute treatment of major depressive disorder: clincical response in an open-label extension trial. J Clin Psychiatry. 2008; 69: 441–451.
19. JP O'Reardon , HB Solvason , PG Janicak , etal. Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiatry. 2007; 62: 1208–1216.
21. LL Carpenter , PG Janicak , ST Aaronson , etal. Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of acute treatment outcomes in clinical practice. Depress Anxiety. 2012; 29(7): 587–596.
22. KR Connolly , A Helmer , MA Cristancho , etal. Effectiveness of transcranial magnetic stimulation in clinical practice post-FDA approval in the United States: results observed with the first 100 consecutive cases of depression at an academic medical center. J Clin Psychiatry. 2012; 73(4): e567–e573.
23. MM Shafi , MB Westover , MD Fox , etal. Exploration and modulation of brain network interactions with noninvasive brain stimulation in combination with neuroimaging. Eur J Neurosci. 2012; 35(6): 805–825.
24. A Pascual-Leone , JM Tormos , J Keenan , etal. Study and modulation of human cortical excitability with transcranial magnetic stimulation. J Clin Neurophysiol. 1998; 15: 333–343.
25. KB Wells , A Stewart , RD Hays , etal. The functioning and well-being of depressed patients—results from the medical outcomes study. JAMA. 1989; 262: 914–919.
26. WE Broadhead , DG Blazer , LK George , etal. Depression, disability days, and days lost from work in a prospective epidemiologic survey. JAMA. 1990; 264: 2524–2528.
27. N Kennedy , K Foy , R Sherazi , etal. Long-term social functioning after depression treated by psychiatrists: a review. Bipolar Disord. 2007; 9: 25–37.
30. LL Judd , HS Akiskal , PJ Zeller , etal. Psychosocial disability during the long-term course of unipolar major depressive disorder. Arch Gen Psychiatry. 2000; 57: 375–380.
31. MH Trivedi , AJ Rush , SR Wisniewski , etal. Factors associated with health-related quality of life among outpatients with major depressive disorder: a STAR*D report. J Clin Psychiatry. 2006; 67(2): 185–195.
32. SR Wisniewski , AJ Rush , C Bryan , etal. Comparison of quality of life measures in a depressed population. J Nerv Ment Dis. 2007; 195(3): 219–225.
33. WV McCall , PB Rosenquist , J Kimball , etal. Health-related quality of life in a clinical trial of ECT followed by continuation pharmacotherapy: effects immediately after ECT and at 24 weeks. J ECT. 2011; 27: 97–102.
34. DA Solomon , AC Leon , W Coryell , etal. Predicting recovery from episodes of major depression. J Affect Disord. 2008; 107: 285–291.
35. JE Ware Jr, CD Sherbourne . The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992; 30: 473–483.
36. R Brooks . EuroQol: the current state of play. Health Policy. 1996; 37: 53–72.
37. R Mann , S Gilbody , D Richards . Putting the “Q” in depression QALYs: a comparison of utility measurement using EQ-5D and SF-6D health related quality of life measures. Soc Psychiatry Psychiatr Epidemiol. 2009; 44(7): 569–578.
41. S Macran , P Kind . “Death” and the valuation of health-related quality of life. Medical Care. 2001; 39(3): 217–227.
42. DJ Katzelnick , FF Duffy , H Chung , etal. Depression outcomes in psychiatric clinical practice: using a self-rated measure of depression severity. Psychiatr Serv. 2011; 62(8): 929–935.
43. Z Cui , DE Faries , S Gelwicks , D Novick , X Liu . Early discontinuation and suboptimal dosing of duloxetine treatment in patients with major depressive disorder: analysis from a US third-party payer perspective. J Med Econ. 2012; 15: 134–144.
44. F Hardeveld , J Spijker , R De Graaf , WA Nolen , AT Beekman . Prevalence and predictors of recurrence of major depressive disorder in the adult population. Acta Psychiatr Scand. 2010; 122: 184–191.
46. DL Dunner , AJ Rush , JM Russell , etal. Prospective, long-term, multicenter study of the naturalistic outcomes of patients with treatment-resistant depression. J Clin Psychiatry. 2006; 67: 688–695.
47. OH Gunther , C Roick , MC Angermeyer , etal. The responsiveness of EQ-5D utility scores in patients with depression: a comparison with instruments measuring quality of life, psychopathology and social functioning. J Affect Disord. 2007; 105: 81–91.
48. P Sobocki , M Ekman , H Agren , etal. Health-related quality of life measured with EQ-5D in patients treated for depression in primary care. Value Health. 2007; 10: 153–160.
49. GE Simon , DA Revicki , L Grothaus , etal. SF-36 summary scores: are physical and mental health truly distinct? Med Care. 1998; 36: 567–572.
50. A Garcia-Cebrian , M Bauer , AL Montejo , etal. Factors influencing depression endpoints research (FINDER): study design and population characteristics. Eur Psychiatry. 2008; 23: 57–65.
51. V Walker , DL Streiner , S Novosel , etal. Health-related quality of life in patients with major depression who are treated with moclobemide. J Clin Psychopharmacol. 1995; 15: 60S–67S.
52. C Reed , BU Monz , DG Perahia , etal. Quality of life outcomes among patients with depression after 6 months of starting treatment: results from FINDER. J Affect Disord. 2009; 113: 296–302.
53. K Kroenke , SL West , R Swindle , etal. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care. JAMA. 2001; 286: 2947–2955.
54. LN Yatham , Y Lecrubier , RR Fieve , etal. Quality of life in patients with bipolar I depression: data from 920 patients. Bipolar Disord. 2004; 6(5): 379–385.
55. MC ten Doesschate , MWJ Koeter , CLH Bockting , etal. Health related quality of life in recurrent depression: a comparison with a general population sample. J Affect Disord. 2010; 120(1–3): 126–132.
56. C Sapin , B Fantino , ML Nowicki , P Kind . Usefulness of EQ-5D in assessing health status in primary care patients with major depressive disorder. Health Qual Life Outcomes. 2004; 2: 20.
57. R Peveler , T Kendrick , M Buxton , etal. A randomised controlled trial to compare the cost-effectiveness of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine. Health Technol Assess. 2005; 9(16): 1–134.